SPLASH BEVERAGE GROUP, INC. 8K

Splash Beverage Group reported improved first-half 2026 results and announced a strategic shift, including CannEpil licensing, a Lupvindol collaboration, and an upcoming rebrand and ticker change to Endovia Health Sciences as it pivots from alcoholic beverages to cannabinoid health sciences.

Splash Beverage Group, Inc. reported its second quarter 2026 results, highlighting a roughly 64% year-over-year reduction in loss from continuing operations for the first half of 2026 driven by significant cost-cutting and simplification of its legacy alcoholic beverage business, while outlining a strategic transformation toward a diversified cannabinoid-focused health sciences platform under the Endovia Health Sciences brand. Following quarter-end, the company executed several strategic initiatives, including entering into an exclusive global license for the pharmaceutical-grade cannabinoid platform CannEpil (initially for drug-resistant epilepsy and later expanded to veterinary applications), initiating a development and collaboration agreement with Lupvindol Biosciences Ltd. to advance CannEpil-based veterinary products through FDA Center for Veterinary Medicine pathways, and preparing for international relaunch of CannEpil in the UK, Ireland, and select Latin American markets. The company also announced a pending corporate name and ticker change on the NYSE American, intended to take effect on August 24, 2026, to reflect its repositioning toward pharmaceutical, veterinary and cannabinoid consumer wellness and beverage opportunities.

Filing Facts

CIK

1553788

Ticker

-

Form

8K

Source Type

sec

Accession

0001731122-26-001114

Alert Tier

7